Semaglutide in Overweight/Obese Patients With Chronic Kidney Disease
Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
Quick Facts
What This Study Found
Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
Key Numbers
Semaglutide 2.4 mg weekly. Inclusion: eGFR ≥25, UACR ≥30, BMI ≥27. Primary endpoint: percentage change in UACR.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
- Published In:
- Nature medicine, 31(1), 278-285 (2025)
- Authors:
- Apperloo, Ellen M(4), Gorriz, Jose L, Soler, Maria Jose, Cigarrán Guldris, Secundino, Cruzado, Josep M, Puchades, Maria Jesús, López-Martínez, Marina, Waanders, Femke, Laverman, Gozewijn D, van der Aart-van der Beek, Annemarie, Hoogenberg, Klaas, van Beek, André P, Verhave, Jacobien, Ahmed, Sofia B, Schmieder, Roland E, Wanner, Christoph, Cherney, David Z I, Jongs, Niels, Heerspink, Hiddo J L
- Database ID:
- RPEP-09960
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09960APA
Apperloo, Ellen M; Gorriz, Jose L; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas; van Beek, André P; Verhave, Jacobien; Ahmed, Sofia B; Schmieder, Roland E; Wanner, Christoph; Cherney, David Z I; Jongs, Niels; Heerspink, Hiddo J L. (2025). Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.. Nature medicine, 31(1), 278-285. https://doi.org/10.1038/s41591-024-03327-6
MLA
Apperloo, Ellen M, et al. "Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.." Nature medicine, 2025. https://doi.org/10.1038/s41591-024-03327-6
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide in patients with overweight or obesity and chron..." RPEP-09960. Retrieved from https://rethinkpeptides.com/research/apperloo-2025-semaglutide-in-patients-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.